FranΓ§aisπ See the interactive version (live chart) β
For Cooper Companies (The), we replayed every analyst price target of the past 12 months and measured the real outcome: 0% were profitable, average return -10% (12 calls). At 3 months: -3% average return (21% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
Not enough scored calls for a reliable ranking.
Is Cooper Companies (The) overvalued, and is it a good time to buy Cooper Companies (The) right now? If you're wondering, here's a recap to make up your own mind: Cooper Companies (The)'s valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Cooper Companies (The) | Sector median (Health Care) |
|---|---|---|
| P/E | 61.7 | 29.4 |
| Forward P/E | 14.2 | 17.1 |
| Net margin | 6% | 12% |
π Cooper Companies (The) trades above its sector median (61.7 vs 29.4) β the market expects higher growth; watch out for disappointment.
π P/E, PEG, marginβ¦: see the glossary
The analyst consensus on Cooper Companies (The) (COO) is "Buy" (21 bullish, 2 bearish calls over 12 months). This is not advice: historically, 0% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $85.00 (+20% vs $70.96), ranging from $66.00 to $103 (11 analysts).
Over 1 year, 0% of analyst targets on Cooper Companies (The) were profitable, for an average return of -10% (across 12 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $85.00 within 12 months, i.e. +20% vs the current price. The most bullish targets $103, the most cautious $66.00.
Note: analyst targets are 12-month (median $85.00, +20%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (0%), and the stock's past trajectory.
Its P/E is 61.7, forward P/E 14.2. A forward P/E lower than the current P/E means earnings are expected to grow.
π See the full interactive analysis of Cooper Companies (The) β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.